Lundbeckfonden Ventures took a board seat at Leiden spinout VarmX as part of a round that will fund development of a treatment for spontaneous bleeding.

The cancer therapy developer boosted its overall funding to more than $200m in a round that included series A backer Takeda Ventures.

Lundbeckfonden Ventures took a board seat at VarmX as part of a $36.2m round that will fund development of a treatment for spontaneous bleeding.

Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.

Stem-cell cancer treatment developer Vor Biopharma has collected more capital from investors including existing backers Johnson & Johnson and PureTech Health.

Gilead-backed AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.

UCHealth and Children’s Hospital Colorado are among the limited partners for the University of Colorado-affiliated healthcare technology fund.

The fund will target early-stage digital health applications, medical devices and therapeutics developed on the Anschutz Medical Campus.

Columbia University’s Vor Biopharma has collected more capital from shareholders including Osage University Partners, Johnson & Johnson and PureTech Health.

UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.